幽门螺杆菌耐药性的研究现状

幽门螺杆菌(Hp)是慢性活动性胃炎和消化性溃疡的主要病因，并与胃癌、MALT淋巴瘤的发生密切相关。众多研究表明，Hp的根除有助于溃疡愈合，可降低胃癌发生的危险性，延缓MALT淋巴瘤的进程。因此，Hp感染的治疗一直是胃肠病领域的研究焦点之一，但随着抗生素的广泛应用和Hp根除治疗的普遍开展，Hp对常用抗生素的原发和继发耐药率呈现逐年上升趋势。随着Hp耐药株的不断增加，对其根治的困难亦随之增加。因此，探讨Hp耐药的发生原因及机制，明确如何避免和克服耐药性的产生将是Hp根除治疗中亟待解决的关键问题。

Antibiotic Resistance of Helicobacter Pylori

Helicobacter pylori ( Hp) is the main cause of chronic active gastritis and peptic ulcer disease, and is directly related to gastric carcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Numerous studies indicated eradication of Hp could promote healing of peptic ulcer, reduce the risk of gastric carcinoma, postpone the process of MALT, so that treatment of Hp infection is one of the foci of gastroenterology. In accompanion with the widespread use of antibiotics, the original and acquired antibiotic resistance of Hp shows an increasing tendency year by year, and the difficulty of Hp eradication is increasing as well. So the key problem to be solved is to study the cause and mechanism of antibiotic resistance, and to elucidate how to avoid and overcome antibiotic resistance.